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Glycoside hydrolase family 9 (GH9) of carbohydrate-processing enzymes
primarily consists of inverting endoglucanases. A subgroup of GH9 enzymes are
believed to act as exo-glucosidases or exo-glucosaminidases, with many being
found in organisms of the family Vibrionaceae, where they are proposed to
function within the chitin-catabolism pathway. Here, it is shown that the GH9
enzyme from the pathogen Vibrio cholerae (hereafter referred to as VC0615) is
active on both chitosan-derived and -glucoside substrates. The structure of
VC0615 at 3.17 A˚ resolution is reported from a crystal form with poor
diffraction and lattice disorder. VC0615 was highly refractory to crystallization
efforts, with crystals only appearing using a high protein concentration under
conditions containing the precipitant poly--glutamic acid (PGA). The structure
is highly mobile within the crystal lattice, which is likely to reflect steric clashes
between symmetry molecules which destabilize crystal packing. The overall
tertiary structure of VC0615 is well resolved even at 3.17 A˚ resolution, which
has allowed the structural basis for the exo-glucosidase/glucosaminidase activity
of this enzyme to be investigated.
1. Introduction
Vibrio cholerae is the pathogen responsible for cholera, a
disease characterized by severe diarrhoea that is estimated to
affect 3 million people worldwide and causes nearly 100 000
deaths per annum (Ali et al., 2015). Bacteria of the family
Vibrionaceae, which includes the Vibrio genus, occur naturally
as members of the marine bacterioplankton community, where
they form part of the bacterial flora of chitinous zooplankton.
Vibrionaceae readily utilize chitin as a source of organic
carbon and nitrogen, and their attachment to chitinous
zooplankton such as copepods has been hypothesized to
provide a nutrient-rich habitat for the bacteria (Heidelberg et
al., 2002). The association of V. cholerae with copepods
contributes significantly to the cholera disease burden, such
that an increased copepod number in water sources is posi-
tively correlated with increased outbreaks of cholera (Huq et
al., 2005). Chitin has also been suggested to directly affect the
physiology of V. cholerae, for example by protecting the
bacteria from cold stress (Amako et al., 1987) or from killing
by gastric acid (Nalin et al., 1979). The key importance of
chitin in the life cycle of V. cholerae and other Vibrionaceae
demands a detailed understanding of the biochemical path-
ways responsible for chitin utilization by these organisms,
many of which contribute significantly to the global disease
burden.
The V. cholerae enzyme VC0615 was initially identified as a
putative inverting exoglucosidase (termed BglA) based on its
ISSN 2053-230X
clear exo activity on cello-oligosaccharides and aryl--gluco-
sides and its apparent lack of activity on -1,4-linked di-
saccharides of GlcN and GlcNAc (Park et al., 2002). Based on
sequence homology, VC0615 was assigned to glycoside
hydrolase family 9 (GH9) of the Carbohydrate-Active
enZymes (CAZy) classification scheme (Cantarel et al., 2009;
The CAZypedia Consortium, 2018), a family primarily asso-
ciated with endoglucanases (‘cellulases’). Given that VC0615
was found in a chitin-utilization operon, this apparent incon-
sistency between specificity and operon perplexed the authors,
as they understood that V. cholerae was unable to metabolize
cellobiose or other higher cello-oligosaccharides.
In 2008, a large-scale assessment of chitin-utilization path-
ways in the Vibrionaceae suggested that VC0615 was in fact a
exo-acting glucosaminidase, the substrate of which was the
GlcN-GlcN-O6-P disaccharide resulting from the import of
chitobiose (GlcN)2 through a phosphotransferase-transport
system (Hunt et al., 2008). [Note: here we use chitobiose to
refer to the -1,4 (GlcN)2 disaccharide and N,N
0-diacetyl-
chitobiose to refer to the -1,4 (GlcNAc)2 disaccharide, as
outlined in the IUPAC–IUB naming convention guidelines
(Nomenclature Committee of IUB and IUPAC–IUB Joint
Commission on Biochemical Nomenclature, 1988).]
More recently, Honda and coworkers showed that a close
(60% identity) homologue of VC0615, PBPRA0520 from
Photobacterium profundum SS9, was indeed a multifunctional
exo-acting glucosaminidase/-glucosidase, with a kcat/Km at
least ten times greater for chito-oligosaccharides compared
with the corresponding cello-oligosaccharides, supporting the
functional assignment of this enzyme as an exo-acting
glucosaminidase active on chitobiose substrates (Honda et al.,
2011). Subsequently, a crystal structure of PBPRA0520
confirmed this enzyme to be an exo-acting GH9, illustrating
that loop extensions (compared with endo-acting GH9
enzymes) blocked the 4 to 2 subsites of the enzyme,
rendering it unable to bind substrates in an endo fashion
(Honda et al., 2016).
To date, 16 different three-dimensional structures are
known for CAZy family GH9. 13 of these known structures
are endoglucanases, reflecting their dominance within the
GH9 family. One structure of a Clostridium thermocellum
cellobiohydrolase (CbhA) has also been reported. Whilst not
strictly an exo-acting enzyme, as it hydrolyses terminal cello-
biose units rather than terminal glucose units, Schubot and
coworkers classified CbhA as an ‘exocellulase’ based on the
closed topology of the active site of the enzyme, which
obstructs the binding of substrates beyond the 2 subsite
(Schubot et al., 2004; Davies et al., 1997). PBPRA0520 and a
closely related enzyme from V. parahaemolyticus (VP2484)
are the only exo-acting GH9 enzymes with solved three-
dimensional structures, although VP2484 has yet to be fully
biochemically characterized.
Here, we report the structure solution of the V. cholerae
enzyme VC0615, which was solved at 3.17 A˚ resolution with
poor-quality data reflecting crystal lattice disorder. In contrast
to previous analyses (Park et al., 2002), we find that VC0615 is
substantially more active on (GlcN)2 than (Glc)2, although the
hydrolysis of glucosides by VC0615 was still sufficient to
determine Michaelis–Menten kinetic parameters for aryl
-glucoside substrates. Despite the inferior data, the 3.17 A˚
resolution structure was sufficient to confirm the structural
basis of how this enzyme functions as an exo-glycosidase
through extended loops from -helices 1–2 and -helices 9–10,
which block substrate binding beyond the 1 subsite.
2. Materials and methods
2.1. Macromolecule production
A synthesized cDNA encoding VC0615, cloned into the
NdeI (50) and XhoI (30) sites of the pET-21a vector, was
purchased from GenScript. This construct contains the full
VC0615 gene followed by a C-terminal hexahistidine tag. The
correctness of the cloned plasmid was verified by sequencing
with the T7-fwd and pET-RP primers (Table 1) prior to use in
protein production.
The pET-21a-VC0615 plasmid was used to transform
chemically competent Escherichia coli BL21 Gold (DE3) cells.
Cells were grown for protein production in Terrific Broth (TB)
containing ampicillin (100 mg ml1) at 37C with shaking.
Upon reaching an optical density at 600 nm (OD600) of 0.8, the
cultures were induced with 0.5 mM isopropyl -d-1-thio-
galactopyranoside (IPTG), followed by incubation at 16C
overnight with shaking.
The cells were harvested by centrifugation at 4000g for
15 min at 4C. The pellet was resuspended in HisTrap buffer A
(20 mM Tris pH 8.0, 500 mM NaCl, 20 mM imidazole, 1 mM
DTT) supplemented with EDTA-free cOmplete protease-
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Table 1
Macromolecule-production information.
Source organism V. cholerae
DNA source Synthesized cDNA
Forward primer T7-fwd, TAATACGACTCACTATAGGG (for
sequencing only)
Reverse primer pET-RP, CTAGTTATTGCTCAGCGG (for
sequencing only)
Cloning vector pET-21a
Expression vector pET-21a
Expression host E. coli BL21 Gold (DE3)
Complete amino-acid sequence
of the construct produced
MLLLTNHIGYETQGPKQAVLLCGQTQLMDD
CVLLVCARSHQTVAKLAIEWHGKVDNWH
QGQFHRIDFSDFTTPGDYYLRLEHTHSA
TFTIARGVLMQRTFSDVLHYFKSQRCSG
QFDQQDKQVPLLSTSTTADVHGGWYDAS
GDVSKYLSHLSYANYLNPQQTPLVVWNM
LKGLAVLQHHSGFASFSRTRLKDEALFG
ADFLRRMQNSEGFFYMTVFDKWSKDTKQ
REICAYATQQGHKSDDYQAGFRQGGGMA
IAALAAAARLDTHGEFTQADYLQAAENG
YWHLKEHNLAYLNDGVENIIDEYCALLA
CCELYRTTENDQYLAQAREWAQRLAKRQ
CSDEQIAHYWSATSNGERPYFHASDAGL
PVIALCEYLNIETDTANYAQLQRVVEQA
CQFELAITQQVSNPFGYPRQYVKGVESA
KRTSFFIAQDNESGYWWQGENARLASLA
SMAYLAQPHLSTAIAKPLEQWSQNALNW
IVGLNPYNMCMLDGHGHNNPDYLPHLGF
FNAKGGVCNGITAGFDDPRDIAFNPAGQ
KDDMLQNWRWGEQWIPHGAWYLLAIISQ
FAHFTAHGEENQLEHHHHHH
inhibitor cocktail (Roche) and bovine pancreatic DNase I
(Sigma), and the cells were lysed by passage through a cell
disruptor (Constant Systems) at a pressure of 172 MPa. The
cell lysate was cleared by centrifugation at 50 000g for 45 min
at 4C and the cleared lysate was immediately applied onto
a 5 ml HisTrap FF crude column (GE Healthcare) pre-
equilibrated with HisTrap buffer A. Following the application
of the lysate, the column was washed with five column volumes
(CV) of HisTrap buffer A to remove unbound protein,
followed by elution of the bound protein using an increasing
linear gradient of HisTrap buffer B (20 mM Tris pH 8.0,
500 mM NaCl, 1000 mM imidazole, 1 mM DTT) over 20 CV.
SDS–PAGE was used to identify fractions containing VC0615,
which were pooled and concentrated to a volume of 5 ml
using a 30 kDa cutoff Vivaspin centrifugal concentrator
(Millipore). This concentrated protein from HisTrap purifi-
cation was purified by size-exclusion chromatography (SEC)
using a S75 16/600 column (GE Healthcare) pre-equilibrated
with SEC buffer (20 mMHEPES pH 7.4, 200 mMNaCl, 1 mM
DTT). SEC fractions containing VC0615 were identified by
SDS–PAGE, pooled and diluted 20-fold in ion-exchange
(IEX) buffer A (20 mM HEPES pH 7.4, 1 mM DTT). The
diluted protein sample was applied onto a 5 ml HiTrap Q HP
column (GE Healthcare) pre-equilibrated in IEX buffer A.
The loaded column was washed with 5 CV IEX buffer A and
eluted with a 20 CV increasing linear gradient of IEX buffer B
(20 mM HEPES pH 7.4, 1500 mM NaCl, 1 mM DTT). SDS–
PAGE identified the main IEX elution peak to contain pure
VC0615, whilst a small shoulder peak eluting at higher NaCl
concentrations contained contaminant proteins.
Fractions containing purified VC0615 were pooled and
diluted with IEX buffer A to adjust the NaCl concentration to
100 mM. Purified protein samples were concentrated using a
30 kDa cutoff Vivaspin centrifugal concentrator and the final
concentrations were calculated by UV absorbance at 280 nm
(A280) using a calculated molar extinction coefficient of
129 720M1 cm1 and a calculated molecular mass of
66 130.81 g mol1.
2.2. Kinetic assays
Enzyme kinetics were determined by measuring the
hydrolysis of the artificial fluorogenic substrate 4-methyl-
umbelliferyl--d-glucopyranoside (4MU--d-Glc; Sigma). In
brief, 50 ml solutions of 4MU--d-Glc at 2 final concentra-
tion in 20 mM sodium phosphate pH 6.5 were prepared in a
96-well microplate (Nunc). To initiate the reaction, 50 ml of
VC0615 at a concentration of 2 mM in 20 mM sodium phos-
phate pH 6.5 was added to each substrate solution, giving final
reaction volumes of 100 ml containing 1 4MU--d-Glc
substrate and 1 mM VC0615. Reactions were monitored
continuously for release of the fluorescent 4MU product over
600 s using a Polarstar microplate reader (BMG Labtech). The
initial reaction rates plotted against the 4MU--d-Glc
substrate concentration were fitted by nonlinear regression to
the Michaelis–Menten equation V = (Vmax[4MU--d-Glc])/
(Km + [4MU--d-Glc]). kcat was determined from Vmax
through the relationship Vmax = kcat[E]. All reactions were
carried out in triplicate.
Reactions using other 4MU glycosides were carried out as
above.
2.3. Thin-layer chromatography (TLC) analyses
All oligosaccharide substrates and standards for digests and
TLC analyses were purchased from Megazyme, except for
(GlcN)2, which was purchased from Sigma. Digest reactions
were carried out in McIlvaine phosphate–citrate buffer pH 6.5
using an oligosaccharide substrate concentration of
10 mg ml1 and 0.5 mM VC0615. 20 ml reaction volumes
containing enzyme and substrate were incubated at 37C with
shaking. At set time points, 2 ml of the reaction mixture was
removed and ‘paused’ by flash-freezing in liquid N2. Following
completion of the reaction time course, all frozen aliquots
were thawed and spotted onto an aluminium foil-backed silica
TLC plate (Sigma).
The TLC plate was run in a 50:25:25 n-butanol:water:acetic
acid solvent system until the solvent front reached 1–2 cm
from the top of the plate. In order to improve the separation
between spots, the TLC plate was dried and rerun a second
time in the same solvent system. Following the second run, the
TLC plate was dried and developed using a p-anisaldehyde
(Sigma) stain (3.7 ml p-anisaldehyde, 1.5 ml acetic acid, 5 ml
concentrated sulfuric acid, 135 ml ethanol) with mild heating.
2.4. SEC-MALLS
SEC-MALLS experiments were run in 20 mM HEPES 7.4,
200 mM NaCl buffer. The injected sample comprised 100 ml
VC0615 at 2.5 mg ml1 in 20 mM HEPES pH 7.4, 100 mM
NaCl, 1 mM DTT. Experiments were conducted on a system
comprising a Wyatt HELEOS II multi-angle light-scattering
detector and aWyatt rEX refractive-index detector linked to a
Shimadzu HPLC system (SPD-20A UV detector, LC20-AD
isocratic pump system, DGU-20A3 degasser and SIL-20A
autosampler). Work was conducted at room temperature
(20  2C). All solvents and buffers were 0.2 mm filtered
before use and a further 0.1 mm filter was present in the flow
path. The Shimadzu LC Solutions software was used to control
the HPLC and ASTRA V software was used for the HELEOS
II and rEX detectors.
All data were analysed using the ASTRA V software.
Molecular masses were estimated using the Zimm fit method
with a degree of 1. A value of 0.18 ml g1 was used for the
protein refractive-index increment (dn/dc).
2.5. Crystallization
Crystallization trials were carried out in sitting-drop
vapour-diffusion format using 96-well Swissci SD-2 plates
(‘MRC’ plates) against a range of commercial screens, with
drops consisting of 120 nl protein and 120 nl reservoir solu-
tion. Initial trials with PEG- and/or salt-based crystallization
screens using an30 mg ml1 stock of VC0615 protein did not
yield any hits. Subsequently, the protein concentration was
increased to 67.5 mg ml1 and a further range of commercial
research communications
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screens were tested. Crystals were found in the PGA screen
(Molecular Dimensions; Hu et al., 2008) under conditions
containing 0.1M Tris buffer pH 7.8 and a combination of PEG
and PGA-LM precipitants. Optimization yielded crystals at
basic pH values across a range of PEG and PGA-LM
concentrations in both sitting-drop and hanging-drop vapour-
diffusion formats. The final crystallization conditions were
0.1M Tris pH 7.5, 5% PGA-LM, 8% PEG 20K in a hanging-
drop vapour-diffusion format using 1 ml protein solution and
1 ml reservoir solution.
Substantial difficulty with cryoprotection was experienced
during the crystal-harvesting process. Harvesting crystals into
a ‘standard’ cryoprotectant consisting of the crystallization
well solution (0.1M Tris pH 7.5, 5% PGA-LM, 8% PEG 20K)
supplemented with 25% ethylene glycol resulted in the crys-
tals rapidly dissolving. Extensive experimentation found that
the stable cryoprotection of crystals necessitated the use of
high concentrations of PGA-LM, although the removal of
PEG 20K did not adversely affect the stability or diffraction of
the crystals. Thus, crystals were harvested into an optimized
cryoprotectant solution consisting of 0.1M Tris pH 7.5, 13%
PGA-LM, 25% ethylene glycol before flash-cooling in liquid
nitrogen for data collection. Crystallization information is
summarized in Table 2.
2.6. Data collection and processing
Data were collected on beamline I03 at Diamond Light
Source (DLS), UK. Images were indexed and integrated with
XDS (Kabsch, 2010), followed by data reduction and scaling
with AIMLESS (Evans & Murshudov, 2013). All calculations
were carried out within the new CCP4i2 interface to the CCP4
software suite (Potterton et al., 2018). Data-collection statistics
are summarized in Table 3.
2.7. Structure solution and refinement
The crystal structure of VC0615 was solved by molecular
replacement (MR) using bothMOLREP (Vagin & Teplyakov,
2010) and Phaser (McCoy, 2007) with a monomer of the GH9
enzyme from V. parahaemolyticus (PDB entry 3h7l; New York
SGX Research Center for Structural Genomics, unpublished
work) as the search model in each case. The top MR solution
from MOLREP found four chains in the asymmetric unit,
whilst the top MR solution from Phaser found five chains.
Closer inspection revealed that electron density for one chain
in the Phaser solution was substantially poorer than for the
others, suggesting either disorder or partial occupancy. It was
decided to leave this chain in the model, as positive Fc  Fo
difference density and higher Rwork and Rfree factors were
observed in its absence.
Because MOLREP incorporates alignment and modifica-
tion of the search model against the target sequence, MR using
Phaser was performed again using a monomer that had been
aligned and modified by MOLREP. The resulting solution
contained five chains in the asymmetric unit, each with the
correct VC0615 sequence. The molecular-replacement solu-
tion from Phaser was subjected to alternating rounds of
manual model building in Coot (Emsley & Cowtan, 2004) and
refinement with REFMAC5 (Murshudov et al., 2011) using
automatically generated local NCS restraints. The refinement
statistics are summarized in Table 4. Quaternary-structure
assemblies were analysed using PISA (Krissinel & Henrick,
2007) and dimer coordinates were generated using the PISA
extension within Coot. Root-mean-square deviations (r.m.s.d.)
were calculated using the SSM superpose function of CCP4mg
(McNicholas et al., 2011). Crystallographic figures were
generated using PyMOL (Schro¨dinger).
3. Results and discussion
3.1. Biochemical characterization of recombinant VC0615
We first characterized the enzymatic activity of purified
recombinant VC0615 using the fluorogenic substrates 4MU-
-d-glucose and 4MU--d-cellobiose. In line with previous
analyses of this enzyme (Park et al., 2002), 4MU--d-glucose
research communications
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Table 3
Data collection and processing.
Values in parentheses are for the outer shell.
Diffraction source I03, DLS
Wavelength (A˚) 0.9762
Temperature (K) 100
Detector PILATUS3 6M
Crystal-to-detector distance (mm) 557.15
Rotation range per image () 0.10
Total rotation range () 220
Exposure time per image (s) 0.040
Space group P3221
a, b, c (A˚) 234.90, 234.90, 129.42
, ,  () 90, 90, 120
Mosaicity () 0.26
Resolution range (A˚) 47.33–3.17 (3.24–3.17)
Total No. of reflections 801107
No. of unique reflections 69816
Completeness (%) 100 (100)
Multiplicity 11.5 (10.8)
hI/(I)i 8.4 (0.9); <2 at 3.5 A˚
Half-set correlation (CC1/2) 1.0 (0.32)
Rp.i.m. 0.08 (0.90)
Overall B factor from Wilson plot (A˚2) 74
Table 2
Crystallization.
Method Sitting-drop vapour diffusion for initial
crystallization trials; hanging-drop
vapour diffusion for optimization trials
Plate type MRC 96-well 2-drop plates for initial
trials; 24-well sterile tissue-culture plates
for optimized conditions
Temperature (K) 293
Protein concentration (mg ml1) 67.5
Buffer composition of protein
solution
20 mM HEPES pH 7.4, 100 mM NaCl,
1 mM DTT
Composition of reservoir
solution
100 mM Tris pH 7.5, 5% PGA-LM, 8%
PEG 20K (final optimized conditions)
Volume and ratio of drop 120 nl protein + 120 nl reservoir solution
(initial trials); 1 ml protein + 1 ml
reservoir solution (final optimized
conditions)
Volume of reservoir 54 ml (initial trials); 500 ml (final optimized
conditions)
was hydrolysed by VC0615, with Michaelis–Menten kinetic
parameters Km = 768 mM and kcat = 1.3 min
1 (Fig. 1a).
Consistent with its reported activity as an exo-acting enzyme,
we were unable to model Michaelis–Menten kinetics for the
hydrolysis of 4MU--d-cellobiose by VC0615, as the release of
4MU was preceded by a lag period reflecting prior hydrolysis
of a 2 glucose before the release of 4MU. No hydrolysis was
observed against 4MU--d-xylose, 4MU--d-GlcNAc or
4MU--d-mannose substrates (Fig. 1b). Honda and coworkers
have previously shown PBPRA0520 from P. profundum (a
close homologue of VC0615) to be a competent exo-
glucosaminidase (Honda et al., 2011). However, we were
unable to measure kinetic parameters for the hydrolysis of
4MU--d-glucosamine by VC0615 owing to a lack of
commercial availability of this substrate.
In order to obtain a semi-quantitative measure of the effi-
ciency of glucosidase versus glucosaminidase activity by
VC0615, we next investigated the hydrolysis of various
oligosaccharides by VC0615 using thin-layer chromatography
(TLC). When cellobiose, cellotriose or cellotetraose were used
as substrates for VC0615, we observed a gradual increase in
glucose monomers and shorter cello-oligosaccharides in the
reaction mixture. The cleavage pattern observed was consis-
tent with the processive removal of single glucose units from
cello-oligosaccharide chains, rather than internal chain
hydrolysis by an endo-glycosidase (Fig. 2a).
When chitobiose (GlcN)2 was used as the substrate for
VC0615, cleavage to the monosaccharide was also observed
(Fig. 2b). Strikingly, a large amount of product was already
visible after 5 min reaction time and VC0615 effected a
complete digestion of the chitobiose substrate within 30 min.
In contrast, a substantial amount of starting material remained
in the cellobiose digest after 1 h (both reactions were initiated
with 10 mg ml1 substrate). These experiments demonstrate
that VC0615 is a substantially more effective exo-glucos-
aminidase than exo-glucosidase, which is in line with previous
observations on PBPRA0520 (Honda et al., 2011) and the lack
of cellulose metabolism shown by Vibrionaceae in general.
Consistent with the 4MU substrate experiments, no digestion
of N,N0-diacetylchitobiose (GlcNAc)2 was observed even after
1 h incubation (Fig. 2c).
3.2. Crystallization and crystal-packing interactions of
VC0615
A first round of crystallization trials of VC0615 were carried
out at 30 mg ml1 protein concentration using a range of
PEG and/or salt precipitant screens. We found no protein
crystals in any of the conditions tested. Subsequently, the
VC0615 concentration was increased to 67.5 mg ml1 and
additional crystallization screens were tested. In this second
round of screening we observed several hits in the PGA screen
(Molecular Dimensions) under conditions containing Tris
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Figure 1
Hydrolysis of fluorogenic substrates by VC0615. (a) Michaelis–Menten
kinetics for the hydrolysis of 4MU--d-glucose by VC0615. Error bars are
standard deviations from three technical replicates. (b) Hydrolytic release
of 4MU from various substrates. Only 4MU--d-glucose and 4MU--d-
cellobiose show any hydrolysis. The release of 4MU from 4MU--d-
cellobiose follows a lag period, consistent with processive hydrolysis by
an exo-acting enzyme. (RFU, relative fluorescence units.)
Table 4
Structure solution and refinement.
Values in parentheses are for the outer shell.
PDB code 6gdt
Resolution range (A˚) 47.33–3.17 (3.24–3.17)
Completeness (%) 100 (100)
No. of reflections, working set 66351
No. of reflections, test set 3411
Final Rcryst 0.23
Final Rfree 0.28
Cruickshank DPI 0.52
No. of non-H atoms
Protein 22634
Chains A–D 18128
Chain E 4506
Ligand 4
Solvent 71
R.m.s. deviations
Bonds (A˚) 0.007
Angles () 1.13
Average B factors (A˚2)
Protein 107
Chains A–D 89.6
Chain E 175.3
Ligand 77
Water 55
Ramachandran plot
Most favoured (%) 93.9
Allowed (%) 4.1
buffer and a combination of PGA-LM and PEG precipitants
(Fig. 3a). Optimization trials indicated that crystallization
favoured basic pH values, with a range of PGA-LM and PEG
concentrations being tolerated. Both sitting-drop and hanging-
drop vapour-diffusion techniques yielded crystals of similar
visual quality. The final crystallization conditions were 0.1M
Tris pH 7.5, 5% PGA-LM, 8% PEG 20K. Crystals typically
appeared within several hours and reached maximum size
within 2 d (Table 2).
Despite the apparent visual quality of the optimized
VC0615 crystals, it became apparent that their suitability for
X-ray diffraction studies was limited. Even after extensive
optimization of the crystallization and cryoprotectant condi-
tions, all crystals of VC0615 tested showed highly smeared
diffraction patterns that were indicative of substantial internal
disorder within the crystal. The most promising crystals of
VC0615, cryoprotected using 13% PGA-LM and 25% ethy-
lene glycol, were sent to beamline I03 at Diamond Light
Source, UK for data collection. The synchrotron diffraction
images were similar in appearance to those collected in-house
(Fig. 3b), although the mosaicity of the data was somewhat
lower than expected (0.26 for the best data set). The best data
set for VC0615 was processed to 3.17 A˚ resolution and was
used for all further calculations (Tables 3 and 4).
The diffraction of the VC0615 crystals indicated a trigonal
space group with a single screw axis along the a axis, matching
either P3121 or P3221. Matthews coefficient analysis suggested
six or seven molecules of protein per asymmetric unit to be the
most likely composition of the VC0615 crystals (with 30 and
40% probability and 53.3 and 45.5% solvent content, respec-
tively), although five or eight molecules per asymmetric unit
were also plausible (with 10 and 15% probability and 61.1 and
37.7% solvent content, respectively).
The VC0615 structure was solved by molecular replacement
using the GH9 enzyme VP2484 from V. parahaemolyticus,
which shares 68% identity with VC0615. The best molecular-
replacement solution from Phaser indicated the correct space
group to be P3221, with five molecules of VC0615 in the
asymmetric unit. Surprisingly, when the same molecular
replacement was conducted with MOLREP using default
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Figure 2
TLC analysis of cello-oligosaccharide and chito-oligosaccharide substrate hydrolysis by VC0615. (a) VC0615 digestion of cello-oligosaccharides effects
the gradual release of glucose and shorter oligosaccharides, consistent with the activity of a processive exo-glycosidase. (b) VC0615 effects the complete
digestion of chitobiose within 30 min, compared with the relatively slow hydrolysis observed for the cello-oligosaccharides. (c) VC0615 does not
hydrolyse N,N0-diacetylchitobiose. In all TLCs, the purple spot corresponds to citrate from the McIlvaine reaction buffer, which was not present in the
standards. The citrate causes some displacement of lower spots. (d.p., degree of polymerization.)
settings, only four molecules of VC0615 were placed. Closer
inspection revealed that whilst electron density for four of the
five chains of VC0615 was clear and well defined, the density
for the fifth chain (hereafter referred to as chain E) was
substantially poorer, bordering on uninterpretable in many
regions. Consistent with this poorer electron density, the B
factors for chain E were substantially higher than for the other
four chains (hereafter referred to as chains A–D) (Fig. 4a).
To establish the degree of oligomerization for VC0615 in
solution, we analysed purified protein by size-exclusion
chromatography coupled to multi-angle laser light scattering
(SEC-MALLS). Purified VC0615 eluted as a single major
peak with a calculated molecular mass of 118 kDa, indi-
cating that the species in solution was likely to be a dimer
(monomer mass of66 kDa; Fig. 4b). PISA analysis (Krissinel
& Henrick, 2007) suggested stable dimers between molecules
of chain A and chain D of an adjacent asymmetric unit, and
also between chain B and chain C of an adjacent asymmetric
unit. Calculated interface areas were 1294.9 A˚2 per molecule
for the A–D dimer and 1289.6 A˚2 per molecule for the B–C
dimer. Given the essentially identical calculated interface
areas between theA–D and B–C dimers, as well as their strong
similarity (r.m.s.d. of 0.32 A˚ over 1129 residues as calculated
by SSM superposition in CCP4mg), this arrangement of
VC0615 is likely to be the biologically relevant dimer present
in solution (Fig. 4c).
Analysis of protein-packing interactions within the VC0615
crystal lattice may provide some explanation for the
substantially poorer electron density observed for chain E.
The crystals of VC0615 appeared to contain a large central
channel parallel to the c axis at the intersection of four
adjacent unit cells, which is bordered by molecules of chain E
(Fig. 4d). Given the dimeric nature of VC0615, we speculated
on the possibility of a sixth ‘chain F’ of VC0615 in crystallo,
which might lie within this central channel as the dimer
partner of chain E. Although some positive Fc Fo difference
density was observed in the central channel, this density was
too poor to model even a small portion of VC0615. Thus, we
examined the effect of adding ‘chain F’ to the VC0615 crystal
structure by modelling its predicted position through the
superposition of the A–D dimer onto chain E. The resulting
hypothetical six-chain model revealed a large steric clash
between ‘chain F’ and a symmetry equivalent along the c axis,
demonstrating that an additional molecule of VC0615 cannot
be readily accommodated in this crystal-packing arrangement
(Fig. 4e). Solving the structure of VC0615 in the lower
symmetry space group P32 did not produce a structure in
which the ‘chain F’ molecules were well resolved, indicating
that the observed symmetry clash was unlikely to result from a
pseudosymmetry operator being mistaken for crystallographic
symmetry in the P3221 structure. Given that ‘chain F’ is the
dimer partner of chain E, difficulty in packing this chain
readily explains the disorder observed for molecules of chain
E within the VC0615 crystal structure.
When the VC0615 structure was refined with only chains
A–D in the asymmetric unit, the Rwork and Rfree factors were
2–3% higher and substantial positive Fc  Fo difference
density could be observed in the region corresponding to
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Figure 3
Crystallization and diffraction of VC0615. (a) Bright-field and UV fluorescence images of VC0615 crystals from PGA screen well G8 (0.1M Tris pH 7.8,
5% PGA-LM, 8% PEG 20K). (b) Diffraction image of a VC0615 crystal on beamline I03 at Diamond Light Source.
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Figure 4
Subunit interactions and crystal packing of VC0615. (a) Asymmetric unit of VC0615 coloured by B factor, showing the substantially higher disorder of
chain E. The map shown is Fc  Fo OMIT density contoured at 0.22 e A˚
3 calculated from refinement of VC0615 without chain E. (b) SEC-MALLS
trace showing a single peak for purified VC0615, containing a species with an estimated molecular mass of 118 kDa, indicating that VC0615 forms a
dimer in solution. (c) Superposition of chainsA andD and chains B and C dimers of VC0615. (d) Packing of VC0615 crystals. A single asymmetric unit is
highlighted in blue (chains A–D) and purple (chain E). Chains A–D and chain E in other asymmetric units are coloured grey and red, respectively. A
central channel surrounded by molecules of chain E can be observed at the intersection of four unit cells. (e) Steric clashes which arise between two
symmetry-related molecules of a hypothetical ‘chain F’ (red and purple) in the VC0615 crystal lattice.
chain E. Thus, we elected to leave chain E modelled in the
final deposited structure (PDB entry 6gdt).
3.3. The structure of VC0615 and its relationship to other
GH9 enzymes
The structure of VC0615 is highly similar to those solved for
GH9 enzymes from P. profundum (PBPRA0520; PDB entry
5dgr; Honda et al., 2016) and V. parahaemolyticus (VP2484;
PDB entry 3h7l; New York SGX Research Center for Struc-
tural Genomics, unpublished work), sharing 60 and 68%
sequence identity, respectively. Superposition using the SSM
superpose function of CCP4mg gives r.m.s.d.s of 0.66 A˚ over
554 residues for VC0615 and PBPRA0520, and 0.59 A˚ over
563 residues for VC0615 and VP2484 (comparing chain A of
each structure).
VC0615 protomers are comprised of two domains: an
N-terminal fibronectin type III (Fn3) domain (amino acids
1–92) and a C-terminal (/)6-barrel domain (93–566) which
contains the active site. The active site of VC0615 (position
inferred from homology to a PBPRA0520–ligand complex;
PDB entry 5dgr) is situated within a series of loops which
emanate from the core helices of the (/)6-barrel (Fig. 5).
Long linkers from -helices 1–2 (residues 112–162) and
-helices 9–10 (404–442) of VC0615 (features that are well
resolved at 3.17 A˚ resolution) contribute to the formation of a
closed-off steric block towards the ‘rear’ face of the binding
pocket, which restricts the active-site binding pocket to only a
single sugar-binding subsite. These long loops distinguish
VC0615 and related exo-acting GH9s from the endo-acting
GH9s, such as Tf-Cel9A cellulase from Thermobifida fusca,
which has much shorter loops linking its -helices (PDB entry
4tf4; Sakon et al., 1997; Fig. 6).
Although not strictly an exo-acting enzyme, the GH9
cellobiohydrolase CbhA from C. thermocellum (PDB entry
1rq5; Schubot et al., 2004) has been reported to contain a
structurally closed binding pocket, albeit one which hydro-
lyses terminal cellobiose rather than terminal glucose units.
Structural comparison of VC0615 and related exo-acting
GH9s with CbhA shows that the linkers from -helices 1 to 2
and 9 to 10 contribute more to steric blocking of the 2
subsite in the true exo-acting enzymes (Fig. 7). Notably, whilst
the loop from -helices 1 to 2 is actually longer in CbhA (117–
183) compared with the exo-acting GH9s (112–162 in
VC0615), the -helix 1–2 loop in exo-acting GH9s is projected
strongly ‘inwards’ towards the active site compared with
CbhA, thus occluding more of the enzyme binding pocket.
The active-site residues are nearly completely conserved
between VC0615, PBPRA0520 and VP2484, with the only
variation being the presence of Phe231 in PBPRA0520,
compared with Tyr at the equivalent position in VC0615 and
VP2484 (Tyr232 in VC0615). Although we attempted to
obtain a ligand complex of VC0615 by soaking crystals with
cellotriose or cellotetraose, these efforts did not produce a
structure with interpretable active-site electron density. Thus,
we examined the active-site interactions in VC0615 via
comparison with a PBPRA0520–glucosamine ligand complex.
Based on homology to PBPRA0520, Asp140 and Glu546 of
VC0615 are postulated to act as the catalytic base and acid
residues of VC0615, respectively, with Asp144 also likely to be
important in coordinating the incoming water nucleophile.
Asp140 and Glu546 are situated 8.4 A˚ apart, consistent with
the typical separation for catalytic residues of an inverting
glycosidase (Davies & Henrissat, 1995). Surprisingly, there
appears to be no structural rationale within the VC0615 (or
PBPRA0520) binding pocket for the observed preference for
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Figure 5
Structure of a VC0615 monomer. (a) Ribbon diagram of VC0615 (chain A), showing the Fn3 (pink) and (/)6-barrel (orange) domains. (b) Active-site
residues of VC0615. Postulated acid and catalytic base residues are annotated.
chito-oligosaccharide over cellulosic substrates. A 1 subsite
glucosamine would be expected to position its 2-amino group
within hydrogen-bonding distance of Tyr148, Tyr232 and
Trp220 of VC0615, none of which are obviously suited for
discriminating the hydrogen-bonding pattern of an amino
group over a hydroxyl and which are also incorrectly oriented
(‘edge on’) to form a cation– interaction with a charged NH3
+.
It is possible that the observed preference of VC0615 for
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Figure 6
Vibrionaceae exo-acting GH9s versus an endo-acting GH9 enzyme. (a) (/)6-domain alignment of the exo-acting GH9s VC0615 (colours as in Fig. 5),
PBPRA0520 (PDB entry 5drq; green) and VP2484 (PDB entry 3h7l; purple), alongside the endo-acting GH9 Tf-Cel9a from T. fusca (PDB entry 4tf4;
teal), in complex with a cleaved cellohexaose substrate (teal sticks; white circles denote enzyme subsites). Extended loops in exo-acting GH9s from
-helices 1 to 2 (black; 112–162 in VC0615 numbering) and -helices 9 to 10 (black; 404–442) form steric blocks which close off the binding pockets of
these enzymes. The corresponding loops in Tf-Cel9a (red; 20–63 and 292–315) are smaller and do not obstruct the substrate-binding cleft. (b) Clustal
Omega (Sievers & Higgins, 2018) alignment of the VC0615, PBPRA0520, VP2484 and Tf-Cel9a sequences, with loop sequences highlighted. The large
disparity in loop sizes causes suboptimal alignment by Clustal Omega in the -helix 9–10 region. Colours are as in (a).
chito-oligosaccharides may arise from factors outside the 1
subsite binding pocket, such as interactions with the departing
+1 sugar.
4. Conclusion
Here, we have reported the structure of the V. cholerae
enzyme VC0615 at 3.17 A˚ resolution. The VC0615 crystal
structure contains two relatively well ordered homodimers of
VC0615 in each asymmetric unit (chainsA andD and chains B
and C in our structure), as well as a fifth highly disordered
molecule of VC0615 (chain E) which appears to lack a dimeric
partner. PISA analysis indicated that a third VC0615 homo-
dimer (chains E and F) cannot be easily accommodated by the
VC0615 crystal lattice owing to steric clashes which would
arise between symmetry-related copies of molecules of ‘chain
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Figure 7
Vibrionaceae exo-acting GH9s versus the C. thermocellum cellobiohydrolase CbhA. (a) The exo-acting GH9s VC0615, PBPRA0520 and VP2484,
alongside an CbhA E795Q mutant (PDB entry 1rq5; grey), in complex with an uncleaved cellotetraose substrate (grey sticks; white circles denote
enzyme subsites). The loops in exo-acting GH9s from -helices 1 to 2 (black; 112–162 in VC0615 numbering) and -helices 9 to 10 (404–442) help to
occlude the2 subsite of exo-acting GH9s. The corresponding loops in CbhA (red; 117–183 and 454–471) do not occlude the2 subsite. The -helix 1–2
loop in exo-acting GH9s projects more ‘into’ the enzyme binding site compared with the same loop in CbhA, creating more of a steric block against –2
subsite binding. (b) Clustal Omega (Sievers & Higgins, 2018) alignment of the VC0615, PBPRA0520, VP2484 and CbhA sequences, with loops
highlighted. Colours are as in (a).
F’. Given the intrinsic dimeric nature of VC0615, it is possible
that ‘chain F’ molecules are present within the VC0615 crystal
lattice, albeit not in a sufficiently ordered fashion to contribute
to X-ray diffraction. Difficulty in packing molecules of ‘chain
F’ within the VC0615 crystal lattice provides a clear expla-
nation for the high degree of disorder observed in molecules
of chain E, and may also be a substantial contributing factor to
the poor diffraction quality of VC0615 crystals in general.
VC0615 forms part of an exo-acting glucosidase/glucos-
aminidase subgroup within the CAZy GH9 family, alongside
previously reported structures of PRPBA0520 and VP2484.
Structural comparison of the exo-acting GH9s with both an
endo-acting GH9 cellulase and a GH9 cellobiohydrolase
illustrate that the loop topologies around the catalytic (/)6
domain are key for delineating substrate accessibility for all
GH9 enzymes. In particular, loops from -helices 1 to 2 and
-helices 9 to 10 cause steric blocks within the (/)6 domain
of exo-acting GH9s, which restrict substrate binding beyond
the 1 subsite.
Some key questions remain regarding the interaction of
exo-acting GH9s such as VC0615 with their substrates. In
particular, no obvious basis for the discrimination of the 1
subsite for GlcN over Glc has yet been discerned in the
structures of VC0615, PBPRA0520 or VP2484, implying the
possibility of GlcN discrimination at the departing +1 subsite
of the enzyme. This is supported by the observation by Honda
and coworkers that whilst (GlcN)2 is hydrolysed by
PBPRA0520 with a kcat/Km almost 15 times greater than for
(Glc)2, the kcat/Km for the hydrolysis of the aryl substrate pNP-
GlcN is only approximately threefold greater than that for
pNP-Glc (Honda et al., 2011). The hypothesis by Hunt and
coworkers that VC0615 acts on a GlcN-GlcN-O6-P substrate
in vivo (Hunt et al., 2008) also remains to be tested, especially
with regard to the potential binding contributions made by an
O6 phosphate at the +1 enzyme subsite. Improved structural
and biochemical understanding of exo-acting GH9 enzymes
will help to shed light on these questions, as well as broader
questions regarding the molecular basis of chitin utilization by
the Vibrionaceae.
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